Moreover, the Phase II LUMINOSITY trial evaluated Teliso-V in patients with NSCLC with c-MET overexpression and showed that Teliso-V produced durable responses in patients, particularly in those with high c-MET expression (40). The gene discussed is MET; the disease is non-small cell lung carcinoma.